Management of Positive H. pylori Testing in Patient Not on PPIs or Antibiotics
In a patient with positive H. pylori stool antigen or serology who was not taking PPIs or antibiotics prior to testing, initiate treatment with 14-day bismuth quadruple therapy as first-line empiric eradication therapy.
Interpreting the Test Results
Since this patient was not on PPIs or antibiotics before testing, you can trust the test results without concern for false negatives 1. Both medications temporarily reduce bacterial load and can produce false negative results on stool antigen tests and urea breath tests, but they do not cause false positives 1. A positive result in the absence of these interfering medications reliably indicates active infection.
Critical Distinction Between Test Types
If serology (IgG) is positive: This requires confirmation with a test for active infection (stool antigen or urea breath test) before treatment, unless there is very high pretest probability such as an active duodenal ulcer 1. Serology remains positive long after eradication (a "serologic scar") and cannot distinguish active from past infection 1.
If stool antigen is positive: This indicates active infection and warrants immediate treatment 1, 2. The stool antigen test has 97.8% sensitivity and 94.9% specificity when patients are not on interfering medications 2.
Treatment Recommendation
Initiate 14-day bismuth quadruple therapy (BQT) as the preferred first-line empiric regimen 3. This is the most strongly recommended treatment when antibiotic susceptibility is unknown, which is the typical clinical scenario in North America.
Alternative First-Line Options
If bismuth quadruple therapy is not feasible:
- Rifabutin triple therapy for 14 days (if no penicillin allergy) 3
- Potassium-competitive acid blocker (PCAB) dual therapy for 14 days (if no penicillin allergy) 3
Important Caveats
Avoid clarithromycin-based triple therapy as empiric first-line treatment due to rising clarithromycin resistance, which increases treatment failure risk 7-fold 4. Similarly, levofloxacin resistance increases failure risk 8.2-fold 4. These regimens should only be used when antibiotic susceptibility is confirmed 3.
Post-Treatment Management
Universal test-of-cure is required for all patients 3. Perform non-serological testing (stool antigen or urea breath test) at least 4 weeks after completing therapy 4. Ensure the patient is off PPIs for at least 2 weeks before test-of-cure to avoid false negative results 1, 4.
If Treatment Fails
For refractory infection after first treatment failure, use "optimized" BQT for 14 days if not previously used, or rifabutin triple therapy if the patient already received optimized BQT 3. Before prescribing alternative antibiotics, identify all contributing factors to treatment failure, including medication adherence, antibiotic resistance, and host factors 4.